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Rapamycin has no effect on fibrosis-associated gene
expression or extracellular matrix accumulation when
administered to animals with established or early
allograft vasculopathy
Gavin J. Murphy, FRCS
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Background: Most patients with functioning heart transplants have established and
progressive chronic allograft vasculopathy, a fibroproliferative process for which
there is no effective treatment. Coronary artery disease is characterized by histologic
evidence of extracellular matrix accumulation (fibrosis). This study compares the
effect of rapamycin administered to rats with established allograft vasculopathy on
histologic indices of disease progression, extracellular matrix accumulation (fibro-
sis), and the expression of genes known to regulate extracellular matrix turnover in
this model.
Methods: Lewis recipients of Fisher 344 rat thoracic to abdominal aorta transplants
were administered rapamycin starting at 8, 12, and 16 weeks posttransplant or no
treatment. Six grafts in each group were harvested at 24 weeks. Vascular remodeling
and collagen accumulation (Sirius red) were measured by computerized histomor-
phometry of aortic sections. mRNA was extracted from frozen tissue, and the
expression of fibrosis-associated genes was studied by means of semiquantitative
reverse transcriptase-polymerase chain reaction.
Results: Rapamycin had no effect on the progression of early or established
allograft vasculopathy with regard to intimal thickening, remodeling, extracel-
lular matrix accumulation, or profibrotic gene expression, regardless of the time
commenced.
Conclusion: The attenuation of the fibroproliferative response in rodents by rapa-
mycin is not seen if the onset of rapamycin therapy is delayed.
Chronic allograft dysfunction (CAD) occurs as a consequence ofa fibroproliferative response to tissue injury. It is defined histo-logically by allograft vasculopathy and organ fibrosis1 and re-sults ultimately in organ dysfunction and failure. The majorityof patients with functioning transplants have established andprogressive CAD,2,3 with allograft vasculopathy detectable us-
ing intracoronary ultrasound in up to 75% of heart transplant recipients at 1
year.4 No therapy to date has been shown to halt the progression of this process.
Rapamycin, a macrolide antibiotic derived from the actinomycete Streptomyces
hygroscopicus, has been shown to attenuate the fibroproliferative response to
injury in rats after mechanical injury and ischemia-reperfusion injury, as well as
in animal models of CAD in vivo.5,6 This study assesses whether rapamycin
administered to rats after the development of allograft vasculopathy had an
effect on histologic indices of disease progression, extracellular matrix (ECM)
accumulation (fibrosis), or the expression of genes known to regulate ECM
turnover in this model.
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Experimental Design and Methodology
Experimental Model
The thoracic aorta to abdominal aorta allograft model as described
by Mennander and colleagues7 was used. A segment of the de-
scending thoracic aorta approximately 3 cm in length was excised,
thoroughly perfused with phosphate-buffered saline, and used as a
transplant. Fisher (F)344 and Lewis (LEW) rats were used as
donors and recipients, respectively. Ischemic injury to the graft
was minimized by immersion in an ice bath at 4°C between proce-
dures. Through a midline laparotomy incision, the segment of thoracic
aorta was anastomosed end to end as an interposition graft to the
recipient abdominal aorta using 9-0 Prolene suture. The graft was
transplanted into a heterotopic position below the renal arteries and
above the bifurcation forming a loop in the recipient abdomen.
Animals were kept in a controlled environment with unlimited
access to feed and water. Graft harvest was performed in heavily
anesthetized rats, after which the animal was allowed to die by
exsanguination.
Drugs
Rapamycin (Sirolimus; Wyeth-Ayerst, Princeton, NJ) was pre-
pared twice weekly as a working solution of 5 mg/mL in distilled
water. Solutions were stored at 4°C and protected from ultraviolet
light exposure. Drugs were administered orally by gavage.
Experimental Groups
All experiments were performed on F344 to LEW allografts,
which received cyclosporine (Neoral; Novartis, East Hanover,
NJ) 5 mg · kg · day for the first 14 days only to attenuate early
acute rejection and induce tolerance. This was followed by a period
without immunosuppression. They were then started on rapamycin
0.5 mg · kg · day at the following times posttransplantation: group 1,
A B
C
Figure 1. Representative photomicrographs of hematoxylin-eosin–stained section of donor rat aorta (A) and aortic
allografts (B) at 24 weeks. Untreated allografts have a dense transmural inflammatory infiltrate associated with intimal
and medial thickening, as well as striking neoadventitia formation. These changes were not attenuated by rapamycin
started at 8, 12, or 16 weeks. Stages of neointimal development at which rapamycin was commenced (C).
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8 weeks; group 2, 12 weeks; group 3, 16 weeks; and group 4, no
rapamycin.
These time points correspond to macrophage and lymphocyte
infiltration and expansive remodeling (8 weeks), early neointimal
development and expansive remodeling (12 weeks), and neointi-
mal thickening and almost complete and expansive remodeling (16
weeks) (Figure 1). Six rats in each group were killed at 24 weeks.
Rapamycin at 0.5 mg · kg · day has been shown to completely
inhibit the development of allograft vasculopathy in this model
when administered from the time of transplantation.8
Allograft Gene Expression Using Reverse
Transcriptase-Polymerase Chain Reaction
Total mRNA was extracted from aortic tissue, and complementary
DNA molecules were synthesized by reverse transcriptase (RT).
These cDNA species were amplified by polymerase chain reaction
(PCR) and quantified in an enzyme-linked immunosorbent assay
system. Relative quantitation was performed by comparison of the
signal intensity to that of the housekeeping gene -actin. These
techniques have been described in more detail elsewhere.9 The
probe and primer sequences used in these experiments have also
been published.10
Histologic Analysis
Segments of the aortic graft were embedded in paraffin wax, and
multiple sections were stained with hematoxylin-eosin. The level
of inflammatory infiltrate was assessed semiquantitatively and
categorized as follows: none (no inflammatory cells visualized),
mild (endothelialitis, inflammatory cell localized to the endothe-
lium), moderate (dense inflammatory cell infiltrate in the inner-
Figure 2. A-C, Results of histologic analysis. Rapamycin has no effect on the development of the neointima or expansive
remodeling whether introduced at 8, 12, or 16 weeks (Kruskall Wallis P > .05 for intimal/medial ratio and vessel
circumference). Median  SD (boxes); 95% CI (whiskers). There was no significant reduction in the severity of the
inflammatory infiltrate between the rapamycin-treated groups (Pearson’s 2 with Yates’ correction P > .05).
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most layer of the vessel wall), or severe (dense inflammatory cell
infiltrate throughout all layers of the vessel wall).
The vessel circumference and area fraction of the intima and
media were quantified using a computer image analysis system.
The intima was defined as the area between the endothelium and
the internal elastic lamina, and the media was defined as the area
between the internal and external elastic laminas. Paraffin-embed-
ded sections were also stained with Sirius red, and the level of
ECM staining was quantified using computerized histomorphom-
etry as described previously.11
Substances Assessed
To take into account all the factors that influence smooth muscle
cell proliferation, migration, and deposition of ECM during neo-
intima formation, the following species were studied with RT-
PCR: matrix metalloproteinase (MMP)2, MMP9, transforming
growth factor (TGF)-, tissue inhibitor of metalloproteinase 1, and
collagen III.
Analysis of Results
The levels of gene expression and histomorphometric measure-
ments of intimal thickening expressed as the intimal media ratio,
vascular remodeling expressed as vessel circumference (of the
internal elastic lamina), and collagen accumulation expressed as a
product of the percentage mean media Sirius red staining and the
medial area were compared using nonparametric statistical analy-
sis. Comparisons of the level of inflammatory infiltrate were per-
formed using Pearson’s chi-square test. Statistical analysis was
performed using the Statistical Package for the Social Sciences
Version 8.0 (SPSS Inc, Chicago, Ill).
Results
Results of Histologic Analysis
Allografts undergo progressive expansive remodeling pro-
cess that is associated with neointima and marked neoad-
ventitia formation (Figure 1 and Figure 2, A, B). There was
no difference between any of the treatment groups in terms
of intimal area, vessel circumference (Figure 2, A, B), or the
severity of the inflammatory infiltrate (Figure 2, C). There
was also no difference between the allograft groups in terms
of relative medial ECM content (Kruskall Wallis P  .05)
(Figure 3).
Results of RT-PCR
There were no significant differences between the groups
for any of the genes studied (Figure 4), although it is
noteworthy that all allograft groups had elevated TGF-,
MMP2, and MMP9 levels relative to the donor aorta.
Discussion
Rapamycin had no effect on the progression of vasculopa-
thy in rat aortic allografts when administered to grafts with
early cellular changes but no neointima or to grafts with
developing or established intimal hyperplasia. The benefi-
cial effect of rapamycin on CAD development in this rodent
model was therefore lost after 8 weeks. There was also no
difference between any of the rapamycin-treated allograft
groups in the expression of genes that regulate the fibro-
proliferative response.
The rapamycin dose used was smaller than in other
studies in which rapamycin was shown to inhibit established
(3 mg · kg · day intraperitoneally [IP]) or de novo CAD
(0.5-6 mg · kg · day IP) in rat allografts.5,12-15 Rapamycin at
the 0.5 mg · kg · day oral dose equates to a serum trough
level of approximately 1 ng/mL in LEW rats.16 This dose
has been shown in previous studies to significantly prolong
rat renal and cardiac allograft survival in the high-responder
Brown Norway (BN) to LEW model16 and to significantly
inhibit the allograft inflammatory infiltrate, intimal hyper-
plasia, and vessel remodeling in the F344 to LEW model.8
However, these serum levels do not correlate with suggested
therapeutic range levels in humans (5-15 ng/mL)17. Higher
oral doses of rapamycin are poorly tolerated by rats, with
significant weight loss reported at doses greater than 0.8 mg
· kg · day.16 It is possible that the rats may have increased
their clearance of the drug over time, and that this study may
have benefited from serum rapamycin levels on the day of
cull. There was no significant inhibition of MMP9 (a cor-
relate of the severity of the inflammatory infiltrate in this
model)18 in rapamycin-treated versus untreated allografts,
however, semiquantitative assessment of the inflammatory
infiltrate indicated attenuation of the inflammatory response
to the treated allografts. This suggests that increased clear-
ance of rapamycin has not occurred. Other criticisms relate
to the use of a high-responder model in the analysis of
factors affecting the development of CAD,12 because the
intense cellular immune response tends to obscure the con-
tribution of other important etiologic mechanisms.
Figure 3. Relative medial ECM content at 24 weeks. There was no
difference between the groups in medial collagen content and
adventitial collagen density (Kruskall Wallis P > .05). Median 
SD (boxes); 95% CI (whiskers). ECM, Extracellular matrix.
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Figure 4. A-E, Gene expression in allografts at 24 weeks (see text). Median  SD (boxes); 95% CI (whiskers);
outliers (*). MMP, Matrix metalloproteinase; TGF, transforming growth factor; TIMP, tissue inhibitor of metallo-
proteinase.
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In 1991, Meiser and colleagues13 reported that rapamy-
cin at 1.5 mg · kg · day inhibited CAD in de novo hetero-
topic rat cardiac allografts in a high-responder BN to LEW
model. BN and LEW rats are mismatched at major human
leukocyte antigen loci (RT-1n versus RT-11), and the devel-
opment of CAD in this model occurs in association with an
intense cell-mediated response with intimal thickening oc-
curring predominantly between 30 and 40 days. Morris and
colleagues5 reported similar findings with femoral artery
allografts in the same high-responder combination. In this
latter study, the importance of inhibiting the early cellular
response was underscored by the diminished efficacy of
rapamycin if administration was delayed. Delaying onset of
rapamycin treatment by 14, 21, or 30 days inhibited the
progression of CAD only at large doses (3 mg · kg · day IP
at 14 and 21 days and 6 mg · kg · day IP at 30 days) and was
of marginal statistical significance only at this later time
point (28% vs 49%, P .03).5 This study did not, however,
consider the effect of rapamycin once intimal hyperplasia
had become established as in the current study. Poston and
colleagues12 subsequently demonstrated reversal of estab-
lished allograft vasculopathy in the low-responder Piebald-
virol-glaxo to August Copenhagen Irish rat cardiac allograft
model, which develops significant intimal thickening be-
tween 30 and 90 days posttransplantation. Rapamycin (3 mg
· kg · day IP) significantly reversed intimal thickening when
administered between 60 and 90 days.12 Significant weight
loss was noted in these animals; therefore it is questionable
whether the observed effect was because of a direct effect of
rapamycin on the fibroproliferative response or simply a
result of drug toxicity.
There are few studies that have demonstrated any regres-
sion of CAD once it is established. In the weakly immuno-
genic Wistar Furth to LEW model, retransplantation to the
donor strain up to 40 days reversed the inflammatory infil-
trate and prevented the development of CAD.19 In high-
responder models, however, retransplantation was seen to
reduce but not prevent the development of CAD. Moreover,
in these stronger models retransplantation after a critical
period reversed the associated cellular infiltrate, whereas the
intimal proliferation not only did not diminish but continued
to worsen.20-22
F344 to LEW rat renal allografts retransplanted to the
F344 strain showed reversal of the process up to a certain
time interval (12 weeks) after which structural changes,
particularly fibrosis, not only did not diminish but continued
to worsen.23 In the same rat strain combination, retransplan-
tation of cardiac allografts to the donor strain was seen to
reduce levels of mononuclear infiltration but not levels of
myointimal proliferation.14 These findings indicate that pro-
gressive organ injury (ie, the fibroproliferative response)
beyond a certain point may become autonomous and alloan-
tigen independent. Of equal importance is the indication
that the initial insults, whether alloantigen dependent or
independent, occurring at an early stage posttransplant are
crucial in the later development of CAD. This study dem-
onstrates that in F344 to LEW allografts, rapamycin does
not seem to affect the fibroproliferative response after 8
weeks. This may be attributable to inadequate immunosup-
pression in a high-responder model (as indicated by persis-
tently elevated MMP9 mRNA levels in allografts); how-
ever, it may also be attributable to a failure of rapamycin to
inhibit later stages of the fibroproliferative response. This
latter suggestion is supported by the elevated MMP2 and
TGF levels in allografts at 24 weeks. In a randomized
clinical trial in renal transplant recipients with biopsy-
proven CAD,24 cyclosporine dose reduction and the admin-
istration of rapamycin did not prevent the progressive de-
cline in renal function. These findings present clinical and
experimental evidence that rapamycin does not attenuate the
fibroproliferative response in allografts once it is estab-
lished.
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